{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T18:26:05Z","timestamp":1778955965025,"version":"3.51.4"},"reference-count":77,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ecl.2025.06.009","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T03:47:14Z","timestamp":1753415234000},"page":"685-702","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Hypophysitis Associated with Immune Checkpoint Inhibitors"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8167-4338","authenticated-orcid":false,"given":"Andrea","family":"Corsello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5070-7771","authenticated-orcid":false,"given":"Rosa Maria","family":"Paragliola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5828-4438","authenticated-orcid":false,"given":"Francesco","family":"Torino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6495-2244","authenticated-orcid":false,"given":"Roberto","family":"Salvatori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ecl.2025.06.009_bib3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ecl.2025.06.009_bib4","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus Durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"issue":"6","key":"10.1016\/j.ecl.2025.06.009_bib5","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1200\/JCO.22.00975","article-title":"Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study","volume":"41","author":"Johnson","year":"2023","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.ecl.2025.06.009_bib6","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.009_bib7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ecl.2025.06.009_bib8","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 Blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ecl.2025.06.009_bib9","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.ecl.2025.06.009_bib10","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1001\/jama.2023.20181","article-title":"Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: the JUPITER-02 randomized clinical trial","volume":"330","author":"Mai","year":"2023","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.ecl.2025.06.009_bib11","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","article-title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial","volume":"17","author":"Kaufman","year":"2016","journal-title":"Lancet Oncol"},{"issue":"10031","key":"10.1016\/j.ecl.2025.06.009_bib12","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ecl.2025.06.009_bib13","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and safety of Durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1\/2 open-label study","volume":"3","author":"Powles","year":"2017","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.009_bib14","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ecl.2025.06.009_bib15","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"issue":"230","key":"10.1016\/j.ecl.2025.06.009_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1016\/j.ecl.2025.06.009_bib17","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis secondary to cytotoxic t-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series","volume":"186","author":"Caturegli","year":"2016","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.009_bib18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2018","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ecl.2025.06.009_bib19","first-page":"9","article-title":"Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials","volume":"10","author":"Wolchok","year":"2010","journal-title":"Cancer Immun"},{"issue":"12","key":"10.1016\/j.ecl.2025.06.009_bib20","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1038\/s41591-022-02095-5","article-title":"IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma","volume":"28","author":"Taylor","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ecl.2025.06.009_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10391","article-title":"Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis","volume":"7","author":"Dubin","year":"2016","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.ecl.2025.06.009_bib22","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/jim-2021-002099","article-title":"Immune checkpoint inhibitor-induced hypophysitis: lessons learnt from a large cancer cohort","volume":"70","author":"Kotwal","year":"2022","journal-title":"J Invest Med"},{"issue":"3","key":"10.1016\/j.ecl.2025.06.009_bib23","doi-asserted-by":"crossref","first-page":"281","DOI":"10.6004\/jnccn.2022.7098","article-title":"Hypophysitis and secondary adrenal insufficiency from immune checkpoint inhibitors: diagnostic challenges and link with survival","volume":"21","author":"Johnson","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.ecl.2025.06.009_bib24","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.ecl.2025.06.009_bib25","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/a-0843-3366","article-title":"A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors","volume":"51","author":"de Filette","year":"2019","journal-title":"Horm Metab Res"},{"issue":"11","key":"10.1016\/j.ecl.2025.06.009_bib26","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2025.06.009_bib27","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"10.1016\/j.ecl.2025.06.009_bib28","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1158\/1078-0432.CCR-14-2353","article-title":"Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study","volume":"21","author":"Min","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ecl.2025.06.009_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.836859","article-title":"Immune checkpoint inhibitor-induced hypophysitis and patterns of loss of pituitary function","volume":"12","author":"Jessel","year":"2022","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.ecl.2025.06.009_bib30","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","article-title":"Ipilimumab 10 mg\/kg versus ipilimumab 3 mg\/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial","volume":"18","author":"Ascierto","year":"2017","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.ecl.2025.06.009_bib31","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1158\/1078-0432.CCR-12-3243","article-title":"Exposure\u2013response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma","volume":"19","author":"Feng","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ecl.2025.06.009_bib32","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17446651.2019.1701434","article-title":"Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment","volume":"14","author":"Di","year":"2019","journal-title":"Expet Rev Endocrinol Metabol"},{"issue":"10","key":"10.1016\/j.ecl.2025.06.009_bib33","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"issue":"18","key":"10.1016\/j.ecl.2025.06.009_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24183214","article-title":"Sex differences in cancer immunotherapy efficacy, biomarkers, and therapeutic strategy","volume":"24","author":"Wang","year":"2019","journal-title":"Molecules"},{"issue":"10","key":"10.1016\/j.ecl.2025.06.009_bib35","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s40266-019-00697-2","article-title":"Efficacy and adverse events of immunotherapy with checkpoint inhibitors in older patients with cancer","volume":"36","author":"van Holstein","year":"2019","journal-title":"Drugs Aging"},{"issue":"5","key":"10.1016\/j.ecl.2025.06.009_bib36","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.3390\/curroncol28050283","article-title":"Safety of immune checkpoint inhibitors in elderly patients: an observational study","volume":"28","author":"Paderi","year":"2021","journal-title":"Curr Oncol"},{"issue":"12","key":"10.1016\/j.ecl.2025.06.009_bib37","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ecl.2025.06.009_bib38","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline","volume":"187","author":"Husebye","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.009_bib39","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12902-019-0335-x","article-title":"Late-onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report","volume":"19","author":"Takeno","year":"2019","journal-title":"BMC Endocr Disord"},{"issue":"4","key":"10.1016\/j.ecl.2025.06.009_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14041057","article-title":"Immune checkpoint inhibitors as a threat to the hypothalamus-pituitary axis: a completed puzzle","volume":"14","author":"Barnabei","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.ecl.2025.06.009_bib41","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1530\/EJE-19-0238","article-title":"Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis","volume":"181","author":"Faje","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.009_bib42","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-56026-5","article-title":"Immune check point inhibitors-induced hypophysitis: a retrospective analysis of the French Pharmacovigilance database","volume":"9","author":"Garon-Czmil","year":"2019","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.ecl.2025.06.009_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9103280","article-title":"Anti-PD1 and Anti-PDL1-induced hypophysitis: a cohort study of 17 patients with longitudinal follow-up","volume":"9","author":"Levy","year":"2020","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.ecl.2025.06.009_bib44","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s11102-021-01141-8","article-title":"Isolated ACTH deficiency induced by cancer immunotherapy: a systematic review","volume":"24","author":"Iglesias","year":"2021","journal-title":"Pituitary"},{"issue":"2","key":"10.1016\/j.ecl.2025.06.009_bib45","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/ERC-18-0320","article-title":"French endocrine society guidance on endocrine side effects of immunotherapy","volume":"26","author":"Castinetti","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"7","key":"10.1016\/j.ecl.2025.06.009_bib46","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.009_bib47","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","article-title":"Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights","volume":"19","author":"Faje","year":"2016","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/j.ecl.2025.06.009_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/jpm13030415","article-title":"Pituitary enlargement and hypopituitarism in patients treated with immune checkpoint inhibitors: two sides of the same coin?","volume":"13","author":"Chiloiro","year":"2023","journal-title":"J Personalized Med"},{"key":"10.1016\/j.ecl.2025.06.009_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1400841","article-title":"Differences in checkpoint-inhibitor-induced hypophysitis: mono- versus combination therapy induced hypophysitis","volume":"15","author":"van der Leij","year":"2024","journal-title":"Front Endocrinol"},{"issue":"10","key":"10.1016\/j.ecl.2025.06.009_bib50","doi-asserted-by":"crossref","first-page":"7925","DOI":"10.1007\/s00432-023-04659-5","article-title":"Immune checkpoint inhibitor-induced hypophysitis: clinical and biochemical features","volume":"149","author":"Esteves-Ferreira","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.009_bib51","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s11102-021-01182-z","article-title":"Differences between immunotherapy-induced and primary hypophysitis-a multicenter retrospective study","volume":"25","author":"Amereller","year":"2022","journal-title":"Pituitary"},{"issue":"10","key":"10.1016\/j.ecl.2025.06.009_bib52","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s40618-020-01226-4","article-title":"Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study","volume":"43","author":"Bai","year":"2020","journal-title":"J Endocrinol Investig"},{"key":"10.1016\/j.ecl.2025.06.009_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.798517","article-title":"Immune checkpoint inhibitor-induced central diabetes insipidus: looking for the needle in the haystack or a very rare side-effect to promptly diagnose?","volume":"12","author":"Barnabei","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.009_bib54","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11102-014-0552-2","article-title":"Metastatic involvement of the pituitary gland: a systematic review with pooled individual patient data analysis","volume":"18","author":"He","year":"2015","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/j.ecl.2025.06.009_bib55","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s11102-020-01034-2","article-title":"Pituitary metastases: presentation and outcomes from a pituitary center over the last decade","volume":"23","author":"Lithgow","year":"2020","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/j.ecl.2025.06.009_bib56","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s11154-024-09881-1","article-title":"Pitfalls in the lab assessment of hypopituitarism","volume":"25","author":"Schilbach","year":"2024","journal-title":"Rev Endocr Metab Disord"},{"issue":"Suppl 1","key":"10.1016\/j.ecl.2025.06.009_bib57","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0306-4530(02)00112-9","article-title":"Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects","volume":"28","author":"Halbreich","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.ecl.2025.06.009_bib58","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.coemr.2020.10.002","article-title":"The hypothalamic pituitary thyroid axis and sleep","volume":"17","author":"Shekhar","year":"2021","journal-title":"Curr Opin Endocr Metab Res"},{"issue":"2","key":"10.1016\/j.ecl.2025.06.009_bib59","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s11102-008-0106-6","article-title":"Drugs and prolactin","volume":"11","author":"Molitch","year":"2008","journal-title":"Pituitary"},{"issue":"2","key":"10.1016\/j.ecl.2025.06.009_bib60","doi-asserted-by":"crossref","first-page":"117","DOI":"10.14310\/horm.2002.1301","article-title":"Thyroid function during critical illness","volume":"10","author":"Economidou","year":"2011","journal-title":"Hormones (Basel)"},{"issue":"6","key":"10.1016\/j.ecl.2025.06.009_bib61","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40618-017-0778-8","article-title":"Thyroid dysfunctions secondary to cancer immunotherapy","volume":"41","author":"Chalan","year":"2018","journal-title":"J Endocrinol Investig"},{"issue":"4","key":"10.1016\/j.ecl.2025.06.009_bib62","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvab022","article-title":"New cutoffs for the biochemical diagnosis of adrenal insufficiency after ACTH stimulation using specific cortisol assays","volume":"5","author":"Javorsky","year":"2021","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.ecl.2025.06.009_bib63","article-title":"Performance of dehydroepiandrosterone sulfate and baseline cortisol in assessing adrenal insufficiency","author":"Han","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2025.06.009_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.840971","article-title":"Grading central diabetes insipidus induced by immune checkpoint inhibitors: a challenging task","volume":"13","author":"Barnabei","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.ecl.2025.06.009_bib65","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejca.2018.03.006","article-title":"Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1","volume":"96","author":"Mekki","year":"2018","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.ecl.2025.06.009_bib66","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1212\/WNL.31.8.998","article-title":"Pituitary metastasis: incidence in cancer patients and clinical differentiation from pituitary adenoma","volume":"31","author":"Max","year":"1981","journal-title":"Neurology"},{"key":"10.1016\/j.ecl.2025.06.009_bib67","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejca.2019.06.020","article-title":"Machine learning defined diagnostic criteria for differentiating pituitary metastasis from autoimmune hypophysitis in patients undergoing immune checkpoint blockade therapy","volume":"119","author":"Mekki","year":"2019","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ecl.2025.06.009_bib68","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ando.2018.07.008","article-title":"Expert opinion on pituitary complications in immunotherapy","volume":"79","author":"Briet","year":"2018","journal-title":"Ann Endocrinol"},{"issue":"3","key":"10.1016\/j.ecl.2025.06.009_bib69","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ecl.2020.04.002","article-title":"The epidemiology of pituitary adenomas","volume":"49","author":"Daly","year":"2020","journal-title":"Endocrinol Metab Clin N Am"},{"issue":"7","key":"10.1016\/j.ecl.2025.06.009_bib70","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1210\/clinem\/dgac161","article-title":"Endocrine autoantibodies determine immune checkpoint inhibitor-induced endocrinopathy: a prospective study","volume":"107","author":"Labadzhyan","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2025.06.009_bib71","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.ecl.2025.06.009_bib72","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1530\/ERC-20-0513","article-title":"Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns","volume":"28","author":"Nguyen","year":"2021","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"10.1016\/j.ecl.2025.06.009_bib73","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1210\/jc.2016-2118","article-title":"Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline","volume":"101","author":"Fleseriu","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ecl.2025.06.009_bib74","doi-asserted-by":"crossref","first-page":"R107","DOI":"10.1530\/EJE-19-0169","article-title":"Management of endocrine disease: immune check point inhibitors-induced hypophysitis","volume":"181","author":"Albarel","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"36","key":"10.1016\/j.ecl.2025.06.009_bib75","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ecl.2025.06.009_bib76","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.0423","article-title":"Estimation of the percentage of us patients with cancer who are eligible for immune checkpoint inhibitor drugs","volume":"3","author":"Haslam","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"Supplement_1","key":"10.1016\/j.ecl.2025.06.009_bib77","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvae163.1353","article-title":"6529 the risk of hypophysitis following treatment with relatlimab+nivolumab appears higher than expected","volume":"8","author":"Chamorro-Pareja","year":"2024","journal-title":"J Endocr Soc"},{"issue":"4","key":"10.1016\/j.ecl.2025.06.009_bib78","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.4158\/ACCR-2019-0585","article-title":"A common pituitary autoantibody in two patients with immune checkpoint inhibitor-mediated hypophysitis: zcchc8","volume":"6","author":"Leiter","year":"2020","journal-title":"AACE clinical case reports"},{"key":"10.1016\/j.ecl.2025.06.009_bib79","doi-asserted-by":"crossref","first-page":"22246","DOI":"10.1073\/pnas.1908079116","article-title":"Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities","volume":"116","author":"Tahir","year":"2019","journal-title":"Proc Natl Acad Sci"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852925000751?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852925000751?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T15:33:22Z","timestamp":1761147202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852925000751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0889852925000751"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2025.06.009","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypophysitis Associated with Immune Checkpoint Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2025.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}